Services - Health Outcomes
"Assessment of treatment outcomes and therapeutic effectiveness using data from real-life clinical practice in primary care"The challenge:
Governments and other healthcare payers, faced with increasing healthcare costs and a wide choice of medical technologies and interventions, have established mechanisms which are intended to limit reimbursement and access to those medical technologies that are able to demonstrate clinical effectiveness and a favourable cost-benefit profile. The procedures and controls used for this purpose range from national market access infrastructures with explicit data requirements, to local formularies, with a common factor that they require robust outcomes research and health economic information in the decision-making processes employed.
In the future, it is anticipated that decisions on how scarce healthcare resources should most efficiently be allocated will be based on information derived from sophisticated information systems available to both purchasers and suppliers of medical technologies.
The solution:
The Full Feature General Practice Research Database (FF-GPRD), which is managed by the GPRD Group within the MHRA, contains detailed medical information on patients in the UK. The FF-GPRD contains longitudinal data from real-life clinical practice on diagnoses, co-morbidity, prescribing (including off-label), co-prescribing, dosage, switching, health outcomes, secondary care referrals, ADRs, patient age, sex, other demographic details and lifestyle factors (e.g.smoking, BMI etc).
Powerful applications
The GPRD can be used to generate evidence to support the preparation of submissions to market access authorities and to publish research papers to influence market-access decision-making. There are a number of relevant study types where GPRD data can be used:
- Burden of disease on the population: incidence and prevalence of disease; natural history of disease; incidence and prevalence of concurrent illness in the population
- Impact on individuals' lifestyles caused by existing treatment regimes
- Changes in risk over calendar time including treatment outcomes
- Cost implications of therapeutic alternatives including referral rates to secondary care
- Level and variability of access to the range of existing treatment options
- Comparison of adverse event rates in drugs of same class or for same indication
- Drug effectiveness - benefits in real-life setting to generate a holistic view of the cost/benefit profile of the drug
- Drug utilisation: demographics; dose titration; duration; indication; co-medication; switching
The GPRD Group is the ONLY provider of updated GPRD data in its original, unprocessed, relational structure.
Download our information sheet